The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

The GBA gene encodes for the lysosomal enzyme glucocerebrosidase (GCase), which
maintains glycosphingolipid homeostasis. Approximately 5–15% of PD patients have …

Parkinson's disease is a synucleinopathy that is characterized by motor dysfunction, death of
midbrain dopaminergic neurons and accumulation of α-synuclein (α-Syn) aggregates …

Alpha-synuclein (α-Syn) is a key protein involved in Parkinson's disease (PD) pathology. PD
is characterized by the loss of dopaminergic neuronal cells in the substantia nigra pars …

Alterations in α-synuclein dosage lead to familial Parkinson's disease (PD), and its
accumulation results in synucleinopathies that include PD, dementia with Lewy bodies …

Adeno-associated viral (AAV) vectors are a rapidly emerging gene therapy platform for the
treatment of neurological diseases. In preclinical studies, transgenes encoding therapeutic …

Parkinson's disease (PD) is the second most common degenerative disorder. Although the
disease was described more than 200 years ago, its pathogenetic mechanisms have not yet …

Converging evidence from genetic, pathological and experimental studies have increasingly
suggested an important role for autophagy impairment in Parkinson's Disease (PD). Genetic …

Gene therapy is at the cusp of a revolution for treating a large spectrum of CNS disorders by
providing a durable therapeutic protein via a single administration. Adeno-associated virus …

Parkinson's disease (PD) is characterized by the accumulation of α-synuclein (α-syn) within
Lewy body inclusions in the nervous system. There are currently no disease-modifying …